Form 4: Sanara MedTech CEO Granted Restricted Stock

Sanara MedTech Inc. CEO Seth D. Yon received a grant of 25,430 restricted common shares, vesting over three years.

Summary

• Seth D. Yon, Chief Executive Officer, Director, and a 10% owner of Sanara MedTech Inc. (SMTI), was granted 25,430 shares of common stock.
• The transaction occurred on March 22, 2026, with a reported acquisition price of $0 per share, indicating a restricted stock grant.
• The grant was made pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan.
• Following this transaction, Seth D. Yon beneficially owns 113,398 shares of common stock.
• The restricted stock will vest in three equal installments, with one-third of the shares vesting on March 22, 2027, March 22, 2028, and March 22, 2029, respectively.
• Vesting is contingent upon Seth D. Yon's continued employment with Sanara MedTech Inc. through each vesting date.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. It's a routine executive compensation action that aligns management's interests with shareholders, but it does not introduce new material financial performance data.

Positives

• The restricted stock grant aligns the long-term interests of the CEO with those of the shareholders, as the value of the compensation is tied to the company's future stock performance.
• The multi-year vesting schedule encourages executive retention and sustained focus on long-term strategic goals.

Negatives

• The grant of new shares could lead to minor dilution for existing shareholders over time as the shares vest, although this is a common practice for equity compensation.

Risks

• The vesting of the restricted stock is conditional on the reporting person's continued employment with the Issuer through each vesting date, meaning the shares could be forfeited if employment ceases prematurely.

Future Outlook

The future outlook indicates a continued commitment from the CEO to Sanara MedTech, with a vesting schedule extending through March 2029, contingent on ongoing employment.

Management Comments

• The grant of restricted stock to the Chief Executive Officer under the 2024 Omnibus Long-Term Incentive Plan signifies the company's strategy to incentivize and retain key leadership.

Industry Context

StockSavvy.ai notes that restricted stock grants are a standard component of executive compensation packages across various industries, particularly in healthcare and biotechnology, to align management incentives with long-term shareholder value creation and ensure executive retention.

Comparison to Industry Standards

• The practice of granting restricted stock with multi-year vesting is a common and accepted method of executive compensation, comparable to practices seen at companies like Integra LifeSciences Holdings Corporation or Smith & Nephew plc, which also utilize equity-based incentives to retain and motivate their leadership.
• The $0 transaction price for a restricted stock grant is standard, as it represents an award rather than a purchase, similar to how many technology and healthcare companies structure their long-term incentive plans.

Stakeholder Impact

• Shareholders: Potential for minor dilution over time as shares vest, but also benefit from increased alignment of executive incentives with long-term company performance.
• Employees: The grant to the CEO may signal the company's commitment to its long-term incentive plans, potentially impacting morale and retention strategies for other key personnel.

Next Steps

• One-third of the granted restricted shares will vest on March 22, 2027, contingent on continued employment.
• Another one-third of the granted restricted shares will vest on March 22, 2028, contingent on continued employment.
• The final one-third of the granted restricted shares will vest on March 22, 2029, contingent on continued employment.

Key Dates

Keywords

Sanara MedTech, SMTI, Restricted Stock, Equity Grant, Executive Compensation, Insider Transaction, Form 4, Seth D. Yon, Long-Term Incentive Plan